Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Oncogene|November 20, 2002
Tumor-specific activation of hTERT-derived promoters by tumor suppressive E1A-mutants involves recruitment of p300/CBP/HAT and suppression of HDAC-1 and defines a combined tumor targeting and suppression systemHans-Christoph Kirch, Sabine Ruschen, Dieter Brockmann, et al.
Cancer Genetics|September 18, 2013
Complementation of non-tumorigenicity of HPV18-positive cervical carcinoma cells involves differential mRNA expression of cellular genes including potential tumor suppressor genes on chromosome 11q13Angela Kehrmann, Ha Truong, Antje Repenning, et al.
Human Immunology|February 17, 2010
Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patientsPhilipp Schütt, Birgit Schütt, Magdalena Switala, et al.
Cancers|February 15, 2022
High Metabolic Dependence on Oxidative Phosphorylation Drives Sensitivity to Metformin Treatment in MLL/AF9 Acute Myeloid LeukemiaLonglong Liu, Pradeep Kumar Patnana, Xiaoqing Xie, et al.
Blood|July 13, 2006
Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant modelIna Rattmann, Veronika Kleff, Ursula R Sorg, et al.
Human Immunology|March 26, 2008
The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patientsPhilipp Schütt, Vera Rebmann, Dieter Brandhorst, et al.
Cancer Immunology, Immunotherapy : CII|March 8, 2005
In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatmentPhilipp Schütt, Ulrike Buttkereit, Dieter Brandhorst, et al.
Annals of Hematology|March 4, 2005
Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survivalPhilipp Schütt, Peter Ebeling, Ulrike Buttkereit, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 13, 2008
Gene therapy of beta(c)-deficient pulmonary alveolar proteinosis (beta(c)-PAP): studies in a murine in vivo modelVeronika Kleff, Ursula R Sorg, Carsten Bury, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 9, 2017
Gene Therapy of βc-Deficient Pulmonary Alveolar Proteinosis (βc-PAP): Studies in a Murine in vivo ModelVeronika Kleff, Ursula R Sorg, Carsten Bury, et al.
Pageof 4